Nautilus Biotechnology Inc
NAUT
Company Profile
Business description
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Contact
2701 Eastlake Avenue East
SeattleWA98102
USAT: +1 206 333-2001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
128
Stocks News & Analysis
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
stocks
Our view of ANZ’s strategic plan
Trying to please customers and shareholders with a simpler and leaner bank.
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.00 | 21.90 | 0.24% |
| CAC 40 | 8,092.08 | 172.46 | 2.18% |
| DAX 40 | 24,214.04 | 22.90 | -0.09% |
| Dow JONES (US) | 46,543.73 | 273.27 | 0.59% |
| FTSE 100 | 9,431.71 | 21.06 | -0.22% |
| HKSE | 25,910.60 | 469.25 | 1.84% |
| NASDAQ | 22,776.56 | 254.86 | 1.13% |
| Nikkei 225 | 47,672.67 | 825.35 | 1.76% |
| NZX 50 Index | 13,307.40 | 30.41 | 0.23% |
| S&P 500 | 6,701.61 | 57.30 | 0.86% |
| S&P/ASX 200 | 8,990.90 | 22.20 | 0.25% |
| SSE Composite Index | 3,912.21 | 46.98 | 1.22% |